Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response

•An AS37-adjuvanted vaccine induced immune responses which maintained for 6 months.•Extensive immune profiling was conducted on a subset of participants.•AS37 increased expression of interferon-inducible genes and serum CXCL10 (IP-10).•AS37 upregulated specific innate immune cells and Ag-specific B and T lymphocytes.•The immune signature is consistent with toll-like receptor 7 engagement.